Sukyung Woo PhD
Sukyung Woo
PhD
Associate Professor
Department of Pharmaceutical Sciences
Specialty/Research Focus
Anticancer Drug Development; Cancer Pharmacology; Combination Therapy; Mathematical Modeling; Ovarian Cancer; Pharmacodynamics; Pharmacokinetics; Quantitative Systems PK/PD Relationships; RNAi Therapeutics
Professional Summary:
My research utilizes pharmacokinetic/pharmacodynamic and systems pharmacology approaches that integrates a systems perspective, mechanistic mathematical modeling and simulation with quantitative experimental lab studies to advance the discovery, development, and clinical use of drugs.
Education and Training:
- Postdoctoral Fellow, National Cancer Institute (NCI) (2010)
- PhD, Pharmaceutical Sciences, State University of New York at Buffalo (2007)
- MS, Pharmacokinetics, Chungnam National University (2001)
- BPharm, Pharmacy, Chungnam National University (1999)
Employment:
- Adjunct Associate Professor, Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center (2020-present)
- Associate Professor, Pharmaceutical Sciences, University at Buffalo (2019-present)
- Associate Professor, Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, College of Pharmacy (2017–2019)
- Investigator, Stephenson Cancer Center at OUHSC (2010–2019)
- Assistant Professor, Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, College of Pharmacy (2010–2017)
- Postdoctoral Fellow, Center for Cancer Research, National Cancer Institute, NIH (2008–2010)
Awards and Honors:
- Edith Kinney Gaylord Presidential Professorship, University of Oklahoma (2019)
- Research Scholar Award, American Cancer Society (2016)
- Young Investigator Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism/Clinical Pharmacology Translational Research, AAPS (2013)
- Cancer Research Training Award Fellowship, Center for Cancer Research, NCI/NIH (2008)
- Graduate Scholar Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism/Clinical Pharmacology Translational Research Section, AAPS (2007)
- AAPS Annual Meeting Travels Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPDM) (2006)
- 2006 Graduate Scholar Award, Pharmaceutical Science, University at Buffalo (2006)
- Teaching Assistant Award, Pharmaceutical Sciences, University at Buffalo (2004)
- Dongbu Foundation Scholarship (1997)
Research Expertise:
- Anticancer drug development, ovarian cancer
- Pharmacokinetics and Pharmacodynamics
- Quantitative systems pharmacology (QSP) approaches: integrates a systems perspective, mechanistic mathematical modeling and simulation with quantitative experimental lab studies to advance the discovery, development, and clinical use of drugs.
Grants and Sponsored Research:
- December 2021–November 2026
Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition
NIH-National Cancer Institute (NCI)
Role: Principal Investigator
$2,000,000 - September 2021–August 2022
Evaluating the Effect of Target Properties on Anti-cancer siRNA Therapeutics
Center for Protein Therapeutics
Role: Principal Investigator
$100,000 - July 2016–June 2022
Overcoming resistance to anti-VEGF therapy with predictive modeling
American Cancer Society
Role: Principal Investigator
$792,000 - June 2016–May 2022
Targeting HPV Consequences in a Cervical Cancer Clinical Trial
NIH/NCI
Role: Co-Investigator
$2,755,370 - December 2016–November 2021
Reprograming Tumor Microenvironment by Nanoparticle
NIH/NCI
Role: Co-Investigator
$1,143,750 - March 2015–January 2021
Photo-unclick Chemistry and Its Application to Near Infrared-activatable Prodrugs
NIGMS/NIH
Role: Co-Investigator
$1,784,850 - August 2017–July 2020
Visible Light-Controlled Combination Strategy for Treating Nonmuscle Invasive Bladder Cancers
DOD CDMRP/PRCRP
Role: Co-Investigator
$529,000 - July 2015–June 2020
Ovarian Cancer Chemoprevention
NCI/NIH
Role: Co-Investigator
$3,072,192 - September 2015–September 2018
PREVENT Cancer Preclinical Drug Development
NIH/NCI
Role: Co-Investigator
$1,888,965 - March 2016–June 2017
Gynecology Oncology Drug Development Fund
Stephenson Cancer Center
Role: Principal Investigator - September 2012–May 2017
Tumor resistant mechanisms to anti-VEGF therapy
NIGMS/NIH
Role: Principal Investigator
$612,000
Journal Articles:
- Subramaniyan B, Rajaputra P, Nguyen L, Li M, Peer CJ, Kindrick J, Figg WD, Woo S, You Y. Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models. Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models. Photochemistry and Photobiology. 2020; 96(3).
- Sharma A, Li M, Thavathiru E, Ibrahim M, Garcia-Contreras L, Benbrook DM, Woo S. A Physiologically Based Pharmacokinetic (PBPK) Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor Bearing Mice.. AAPS Journal. 2020; 22(2).
- Jaiprasart P, Dogra S, Neelakantan D, Devapatla B, Woo S. Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy. Oncotarget. 2020; 11(1).
- Nguyen L, Li M, Woo S, You Y. Development of Prodrugs for PDT-based Combination Therapy Using a Singlet Oxygen Sensitive Linker and Quantitative Systems Pharmacology. Journal of Clinical Medicine. 2019; 8(12).
- Li M, Nguyen L, Subramaniyan B, Bio M, Peer CJ, Kindrick J, Figg WD, Woo S*, You Y* (*Equal corresponding author). PBPK Modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Journal of Controlled Release. 2019; 308.
- Neelakantan D, Dogra S, Devapatla B, Jaiprasart P, Mukashyaka MC, Janknecht R, Dwivedi SK, Bhattacharya R, Husain S, Ding K, Woo S. Multifunctional APJ pathway promotes ovarian cancer progression and metastasis. Molecular Cancer Research. 2019; 17(6).
- Sharma A, Benbrook DM, Woo S. Pharmacokinetics and Interspecies Scaling of SHetA2, a Novel Oral Agent for Cancer Prevention and Treatment. PLOS ONE. 2018; 13(4).
- Jaiprasart P, Yeung BZ, Wientjes MG, Woo S, Au JLS. Anionic drug reduces intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. Journal of Controlled Release. 2018; 270.
- Wang J, Yeung BZ, Cui M, Peer CJ, Lu Z, Figg WD, Wientjes WG, Woo S, Au JLS. Exosomes is a mechanism of intercellular drug transfer. Journal of Controlled Release. 2017; 268.
- Li M, Thapa P, Rajaputra P, Bio M, Peer CJ, Figg WD, You Y, Woo S. Quantitative Modeling of the Dynamics and Intracellular Trafficking of Far-Red Light-Activatable Prodrugs: Implications in Stimuli-Responsive Drug Delivery System.. J Pharmacokinet and Pharmacodyn. 2017; 44(6).
Professional Memberships:
- American Society of Clinical Pharmacology and Therapeutics (2013–present)
- American Association of Cancer Research (2012–present)
- International Society of Pharmacometrics (2011–present)
- American Association of Pharmaceutical Scientists (2002–present)
Service Activities:
- NRG Oncology, Gynecology-Translation Committee; Member (2019–present)
- Protocol Review and Monitoring Committee (PRMC); Member (2018–2019)
- Graduate Affairs Committee, Basic Sciences Subcommittee; Chair (2018–2019)
- Institutional Biosafety Committee (IBC); Member (2017–2019)